Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
http://ow.ly/CHub30gzHry.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731771 | PMC |
| http://dx.doi.org/10.1183/23120541.00100-2017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Steady Quiet Asthma Without Biologics: One-Year Outcomes of Single-Inhaler Triple Therapy for Severe Asthma with Small Airway Dysfunction.
J Clin Med
August 2025
Respiratory Diseases, University of Bari, 70121 Bari, Italy.
Small airway dysfunction (SAD) plays a critical role in the management of severe asthma, particularly in patients at risk of requiring biological therapies (BTs). Short-term studies have shown that switching to single-inhaler triple therapy (SITT) with extrafine beclomethasone-formoterol-glycopyrronium improves outcomes and helps achieve quiet asthma, a state marked by symptom control, no exacerbations or oral steroids, reduced inflammation, and better small airway function. This study investigated whether, over one year, patients could maintain this state as Steady Quiet Asthma (SQA) and whether baseline measures could predict this sustained response.
View Article and Find Full Text PDFThe effect of intrapulmonary percussive ventilation on clinical parameters and the deposition of inhalation products in patients with stable COPD.
BMC Pulm Med
July 2025
Centre for Research and Innovation in Care, Faculty of Medicine and Health Sciences, University of Antwerp, Kontich, Antwerp, B-2550, Belgium.
Background: Intrapulmonary percussive ventilation (IPV) has demonstrated efficacy in acute settings for treating chronic obstructive pulmonary disease (COPD) exacerbations. Its routine use as an airway clearance technique in stable COPD patients lacks strong scientific support.
Purpose: This study assessed the impact of 4 weeks of IPV treatment in nonhospitalized patients with stable COPD by clinical endpoints, parameters obtained by quantified CT-thorax and a deposition study of inhaled compounds.
Impact of smoking on asthma control with extrafine beclomethasone/formoterol: post hoc analysis of a prospective cohort study.
J Asthma
July 2025
Department of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.
Objective: Exposure to tobacco smoke is a major risk factor for poor asthma control. We aimed to assess the response to asthma treatment based on patients' smoking status.
Methods: This post hoc analysis used data from a large prospective asthma cohort treated with inhaled extrafine beclomethasone/formoterol.
Real-World Effectiveness of Triple Extrafine Fixed-Dose Combination with Beclomethasone/Formoterol/Glycopyrronium on Symptoms and Lung Function in COPD: A Systematic Review and Meta-Analysis.
Int J Chron Obstruct Pulmon Dis
June 2025
Respiratory Disease and Lung Function Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Introduction: Chronic obstructive pulmonary disease (COPD) is a significant global health issue characterized by persistent airflow limitation and inflammation. Triple fixed-dose combinations (FDCs) of inhaled corticosteroids (ICS), long-acting β2-agonists (LABA), and long-acting muscarinic antagonists (LAMA) show promise by potentially enhancing bronchodilation and anti-inflammatory effects. Although randomized controlled trials (RCTs) provide efficacy data, they may not fully represent real-world clinical practice, highlighting the value of real-world evidence (RWE).
View Article and Find Full Text PDFManaging Small Airways Dysfunction in COPD Patients in Real Life Under Fixed Triple Combination of Beclomethasone/Formoterol/Glycopyrronium: The MASCOT Real World Evidence Study.
Int J Chron Obstruct Pulmon Dis
May 2025
Pulmonology Department, 424 Army General Hospital, Thessaloniki, Greece.
Introduction: The efficacy of the fixed extrafine combination of beclomethasone/formoterol/glycopyrronium (BDP/FF/G 87/5/9 μg) has been evaluated in randomized controlled trials of patients with chronic obstructive pulmonary disease (COPD). However, only few data exist on its effectiveness on small airways dysfunction (SAD).
Methods: The MASCOT (MAnaging Small airways dysfunction in COPD patients in real life on the fixed Triple combination of BDP/FF/G 87/5/9 μg pMDI) prospective observational study evaluated the effectiveness of this combination on SAD in a period of 4 weeks, after direct switch from long-acting β-agonists (LABA) and long-acting muscarinic antagonists (LAMA) in COPD patients with SAD (forced expiratory flow at 25-75% of the vital capacity, FEF25-75% <60% predicted).